Dr Brian Godman reviews Mr Gustaf Befrits’ paper on the case for biosimilars from a payer’s perspective. Biosimilars are increasingly important to payers with growing resource pressures. However, key issues need addressing to fully capture their benefits.
No takes yet. Share an insight, caveat, or question.
Brian Godman (2013) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: